Doris Leithner1,2,3, Thomas H Helbich3, Blanca Bernard-Davila4, Maria Adele Marino1,5, Daly Avendano1,6, Danny F Martinez1, Maxine S Jochelson1, Panagiotis Kapetas3, Pascal A T Baltzer3, Alexander Haug7,8, Marcus Hacker7, Yasemin Tanyildizi9, Elizabeth A Morris1, Katja Pinker10,3. 1. Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt, Germany. 3. Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Biomedical Sciences and Morphologic and Functional Imaging, University of Messina, Messina, Italy. 6. Department of Breast Imaging, Breast Cancer Center TecSalud, ITESM Monterrey, Nuevo Leon, Mexico. 7. Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria. 8. Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, Austria; and. 9. Department of Neuroradiology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany. 10. Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, New York, New York pinkerdk@mskcc.org.
Abstract
The rationale was to assess whether there are differences in multiparametric 18F-FDG PET/MRI biomarkers of contralateral healthy breast tissue in patients with benign and malignant breast tumors. Methods: In this institutional review board-approved prospective single-institution study, 141 women with imaging abnormalities on mammography or sonography (BI-RADS 4/5) underwent combined 18F-FDG PET/MRI of the breast at 3T with dynamic contrast-enhanced MRI, diffusion-weighted imaging, and the radiotracer 18F-FDG. In all patients, the following imaging biomarkers were recorded for the contralateral (tumor-free) breast: breast parenchymal uptake (BPU) (from 18F-FDG PET), mean apparent diffusion coefficient (from diffusion-weighted imaging), background parenchymal enhancement (BPE), and amount of fibroglandular tissue (FGT) (from MRI). Appropriate statistical tests were used to assess differences in 18F-FDG PET/MRI biomarkers between patients with benign and malignant lesions. Results: There were 100 malignant and 41 benign lesions. BPE was minimal in 61 patients, mild in 56, moderate in 19, and marked in 5. BPE differed significantly (P < 0.001) between patients with benign and malignant lesions, with patients with cancer demonstrating decreased BPE in the contralateral tumor-free breast. FGT approached but did not reach significance (P = 0.055). BPU was 1.5 for patients with minimal BPE, 1.9 for mild BPE, 2.2 for moderate BPE, and 1.9 for marked BPE. BPU differed significantly between patients with benign lesions (mean, 1.9) and patients with malignant lesions (mean, 1.8) (P < 0.001). Mean apparent diffusion coefficient did not differ between groups (P = 0.19). Conclusion: Differences in multiparametric 18F-FDG PET/MRI biomarkers, obtained from contralateral tumor-free breast tissue, exist between patients with benign and patients with malignant breast tumors. Contralateral BPE, BPU, and FGT are decreased in breast cancer patients and may potentially serve as imaging biomarkers for the presence of malignancy.
The rationale was to assess whether there are differences in multiparametric 18F-FDG PET/MRI biomarkers of contralateral healthy breast tissue in patients with benign and malignant breast tumors. Methods: In this institutional review board-approved prospective single-institution study, 141 women with imaging abnormalities on mammography or sonography (BI-RADS 4/5) underwent combined 18F-FDG PET/MRI of the breast at 3T with dynamic contrast-enhanced MRI, diffusion-weighted imaging, and the radiotracer 18F-FDG. In all patients, the following imaging biomarkers were recorded for the contralateral (tumor-free) breast: breast parenchymal uptake (BPU) (from 18F-FDG PET), mean apparent diffusion coefficient (from diffusion-weighted imaging), background parenchymal enhancement (BPE), and amount of fibroglandular tissue (FGT) (from MRI). Appropriate statistical tests were used to assess differences in 18F-FDG PET/MRI biomarkers between patients with benign and malignant lesions. Results: There were 100 malignant and 41 benign lesions. BPE was minimal in 61 patients, mild in 56, moderate in 19, and marked in 5. BPE differed significantly (P < 0.001) between patients with benign and malignant lesions, with patients with cancer demonstrating decreased BPE in the contralateral tumor-free breast. FGT approached but did not reach significance (P = 0.055). BPU was 1.5 for patients with minimal BPE, 1.9 for mild BPE, 2.2 for moderate BPE, and 1.9 for marked BPE. BPU differed significantly between patients with benign lesions (mean, 1.9) and patients with malignant lesions (mean, 1.8) (P < 0.001). Mean apparent diffusion coefficient did not differ between groups (P = 0.19). Conclusion: Differences in multiparametric 18F-FDG PET/MRI biomarkers, obtained from contralateral tumor-free breast tissue, exist between patients with benign and patients with malignant breast tumors. Contralateral BPE, BPU, and FGT are decreased in breast cancerpatients and may potentially serve as imaging biomarkers for the presence of malignancy.
Authors: Norman F Boyd; Helen Guo; Lisa J Martin; Limei Sun; Jennifer Stone; Eve Fishell; Roberta A Jong; Greg Hislop; Anna Chiarelli; Salomon Minkin; Martin J Yaffe Journal: N Engl J Med Date: 2007-01-18 Impact factor: 91.245
Authors: Valencia King; Jennifer D Brooks; Jonine L Bernstein; Anne S Reiner; Malcolm C Pike; Elizabeth A Morris Journal: Radiology Date: 2011-04-14 Impact factor: 11.105
Authors: K Pinker; H Bickel; T H Helbich; S Gruber; P Dubsky; U Pluschnig; M Rudas; Z Bago-Horvath; M Weber; S Trattnig; W Bogner Journal: Eur Radiol Date: 2013-03-16 Impact factor: 5.315
Authors: Etta D Pisano; Constantine Gatsonis; Edward Hendrick; Martin Yaffe; Janet K Baum; Suddhasatta Acharyya; Emily F Conant; Laurie L Fajardo; Lawrence Bassett; Carl D'Orsi; Roberta Jong; Murray Rebner Journal: N Engl J Med Date: 2005-09-16 Impact factor: 91.245
Authors: Bas B Koolen; Femke van der Leij; Wouter V Vogel; Emiel J Th Rutgers; Marie-Jeanne T F D Vrancken Peeters; Paula H M Elkhuizen; Renato A Valdés Olmos Journal: Acta Oncol Date: 2013-05-14 Impact factor: 4.089
Authors: Deep K Hathi; Wen Li; Youngho Seo; Robert R Flavell; John Kornak; Benjamin L Franc; Bonnie N Joe; Laura J Esserman; Nola M Hylton; Ella F Jones Journal: Sci Rep Date: 2020-12-14 Impact factor: 4.379